Science 37® Furthers Global Expansion with Capabilities in China and Russia to Advance Decentralized Clinical Trials and Accelerate Development
December 07 2021 - 7:55AM
Science 37, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating
System, today announced it has added capability to meet regulatory
requirements and deploy its full-stack, end-to-end technology
platform into China and Russia—further extending penetration into
the Asia-Pacific market and providing sponsors the ability to more
effectively run global decentralized clinical trials.
“By strengthening our presence around the world and bolstering
our Operating System, we’re enabling sponsors to execute clinical
research with faster enrollment and better retention for a more
representative patient population,” said Elisa Cascade, Chief
Product Officer of Science 37. “This is increasingly important, not
only for studies in China and Russia, but also as we build a more
patient-centric future where it’s easier for anyone to participate
in clinical trials from anywhere.”
In addition to expanding global capacity, Science 37 continues
to enhance its purpose-built technology platform to support today’s
more agile clinical trials now available in nearly 95 countries and
in more than 45 languages—ensuring a seamless user experience for a
myriad of international stakeholders.
“With our Operating System, including our proprietary technology
platform and extensive global specialized networks of patient
communities, telemedicine investigators, mobile nurses, and remote
coordinators, we offer the flexibility to deliver agile clinical
trials worldwide,” said Ms. Cascade. “By doing so, we can enable
universal access to patients and providers anywhere and help to
accelerate the development of treatments that impact patients'
lives.”
About Science 37Science 37 Holdings, Inc.’s (Nasdaq: SNCE)
mission is to enable universal access to clinical research — making
it easier for patients and providers to participate from anywhere
and helping to accelerate the development of treatments that impact
patient lives. As a pioneer of decentralized clinical trials, the
Science 37 Clinical Trial Operating System (OS) supports today’s
more agile clinical research designs with its full stack,
end-to-end technology platform and specialized networks of patient
communities, telemedicine investigators, mobile nurses, remote
coordinators and connected devices. Configurable to enable almost
any study type, the Science 37 OS enables up to 15x faster
enrollment, 28% better retention and 3x more diverse patient
population with industry-leading workflow orchestration, evidence
generation and data harmonization. For more information, visit
https://www.science37.com.
MEDIA INQUIRIES
Margie KoomanScience 37Phone: (984) 377-3737Email:
pr@science37.com
INVESTOR RELATIONS:Caroline
PaulGilmartinInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jul 2023 to Jul 2024